GF07

**GF07** is an investigational intravenous compound ginsenoside-paclitaxel liposomal injection developed using Xiamen Ginposome Pharmaceutical's ginsenoside-based Ginposome liposome platform. The formulation combines paclitaxel with ginsenoside in a phospholipid liposome; paclitaxel exerts antineoplastic activity by stabilizing microtubules and disrupting mitosis. The sponsor describes the ginsenoside component as serving drug, liposomal membrane-material, and targeting roles, and reports intended advantages including active tumor targeting, mitigation of multidrug resistance, and reduced metastatic potential; the specific molecular basis of these asserted ginsenoside-mediated effects has not been publicly defined. ([ginposome.cn](https://www.ginposome.cn/aboutus.html))

Other names

compound ginsenoside-paclitaxel liposomepaclitaxel ginsenoside liposome injection注射用复方人参皂苷紫杉醇脂质体注射用复方紫杉醇人参皂苷脂质体